Keytruda meets primary endpoint as perioperative treatment regimen in resected, locally advanced HNSCC

FDA approves Keytruda combination for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)

FDA granted traditional approval to Merck’s pembrolizumab (Keytruda) with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (CPS ≥1).

March 21, 2025

Vol.51 No.11

Clinical Roundup

Chemo-immunotherapy approach shows potential benefit in advanced HPV-negative head-and-neck cancer

Researchers from the University of Chicago Medicine Comprehensive Cancer Center demonstrated the potential of a novel treatment approach including immunotherapy to treat advanced human papillomavirus-negative head-and-neck squamous cell carcinoma. More than half of study participants had 50% or more of their tumors shrink after receiving the immunotherapy drug nivolumab with chemotherapy, followed by response-adaptive chemo-radiation therapy.

March 14, 2025

Vol.51 No.10

Clinical Roundup

First FDA-approved robot-assisted microsurgery for head-and-neck cancer performed at Cedars-Sinai

Cedars-Sinai performed the first robot-assisted microsurgical head-and-neck cancer reconstructive surgery in the United States after the robot device received FDA approval for the procedure.

February 21, 2025

Vol.51 No.07

Clinical Roundup

Nivolumab demonstrates superiority over standard of care for head-and-neck cancer in phase III trial

The Groupe d’Oncologie Radiothérapie Tête Et Cou, also known as the Head and Neck Oncology and Radiotherapy Group or GORTEC, announced that the randomized phase III CheckMate -9KW/NIVOPOSTOP GORTEC 2018-01 trial evaluating nivolumab (Opdivo) as a post-operative treatment component for resected patients with locally advanced squamous cell carcinoma of head and neck with high risk of relapse met its primary endpoint of disease-free survival across all comers.

January 17, 2025

Vol.51 No.02

Clinical Roundup

Phase III trial of subcutaneous pembrolizumab with berahyaluronidase alfa meets primary endpoints

Merck announced positive topline results from the pivotal phase III MK-3475A-D77 trial.

November 22, 2024

Vol.50 No.44

In Brief

LSU Health New Orleans receives $3.1M grant to study head-and-neck cancer incidence in people living with HIV

LSU Health New Orleans was awarded a five-year, $3.1 million grant from the National Institute of Dental and Craniofacial Research.

November 15, 2024

Vol.50 No.43

Keytruda meets primary endpoint as perioperative treatment regimen in resected, locally advanced HNSCC

YOU MAY BE INTERESTED IN

FDA approves Keytruda combination for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)

Chemo-immunotherapy approach shows potential benefit in advanced HPV-negative head-and-neck cancer

First FDA-approved robot-assisted microsurgery for head-and-neck cancer performed at Cedars-Sinai

Nivolumab demonstrates superiority over standard of care for head-and-neck cancer in phase III trial

Phase III trial of subcutaneous pembrolizumab with berahyaluronidase alfa meets primary endpoints

LSU Health New Orleans receives $3.1M grant to study head-and-neck cancer incidence in people living with HIV

Renew today!

Subscriber content

Keytruda meets primary endpoint as perioperative treatment regimen in resected, locally advanced HNSCC

YOU MAY BE INTERESTED IN

FDA approves Keytruda combination for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)

Chemo-immunotherapy approach shows potential benefit in advanced HPV-negative head-and-neck cancer

First FDA-approved robot-assisted microsurgery for head-and-neck cancer performed at Cedars-Sinai

Nivolumab demonstrates superiority over standard of care for head-and-neck cancer in phase III trial

Phase III trial of subcutaneous pembrolizumab with berahyaluronidase alfa meets primary endpoints

LSU Health New Orleans receives $3.1M grant to study head-and-neck cancer incidence in people living with HIV

FDA approves Keytruda combination for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)